Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-07-20
Broadhurst Vanessa Files Johnson & Johnson (JNJ) Form 4 - July 20, 2026
Broadhurst Vanessa traded 46.1K JNJ shares worth $8.8M in this Form 4 filing, reported to the SEC on 2026-07-20.
- Insider
- Broadhurst Vanessa
- Issuer
- Johnson & Johnson JNJ · NYSE
- Filed
- Period
- 2026-07-20
- Accession
- 0000200406-26-000148
- Source
- Official filing on sec.gov ↗
Transactions (3)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Broadhurst Vanessa | 2026-07-20 | Buy | 11.1K | $129.51 | $1.4M | Direct |
| Broadhurst Vanessa | 2026-07-20 | Buy | 11.9K | $131.94 | $1.6M | Direct |
| Broadhurst Vanessa | 2026-07-20 | Sell | 23.1K | $251.27 | $5.8M | Direct |
| Net change | 0 | −$2.8M | ||||
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Track JNJ insider activity
Get alerted when Johnson & Johnson executives buy or sell their shares.